Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.

por Hoffmann, R., Müller, I., Neuber, K., Lassmann, S., Buer, J., Probst, M., Oevermann, K., Franzke, A., Kirchner, H., Ganser, A., Atzpodien, J.
Publicado 1998

Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (A...

por Atzpodien, J, Neuber, K, Kamanabrou, D, Fluck, M, Bröcker, E B, Neumann, C, Rünger, T M, Schuler, G, von den Driesch, P, Müller, I, Paul, E, Patzelt, T, Reitz, M
Publicado 2002